GlassScriptPhysician profile
Mark Durant Davis
NPI 1679580435
$1,038,650.45
in general payments reported to CMS, 2019-2025
68 companies · $227K in 2025
The $227K reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $139K · 2022: $303K · 2023: $151K · 2024: $219K · 2025: $227K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $362K · Travel and Lodging: $135K · Consulting Fee: $37K · Food and Beverage: $28K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $26K · Honoraria: $7,098 · Education: $598.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $362,437.60 |
| Travel and Lodging | $135,309.85 |
| Consulting Fee | $36,756.97 |
| Food and Beverage | $28,099.45 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $26,474.97 |
| Honoraria | $7,097.50 |
| Education | $597.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $274,788.67 | 2021-2025 | Darzalex, Carvykti, Tecvayli |
| Glaxosmithkline, LLC. | $200,966.76 | 2021-2025 | Ojjaara, Blenrep |
| Incyte Corporation | $104,327.46 | 2021-2025 | Monjuvi, Jakafi, Monjuvi |
| Sobi, INC | $83,012.08 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $70,033.86 | 2021-2025 | Ninlaro, Iclusig, Fruzaqla |
| Cti Biopharma Corp. | $57,768.57 | 2022-2023 | Vonjo |
| E.R. Squibb & Sons, L.L.C. | $42,128.62 | 2021-2025 | Reblozyl, Opdivo, Krazati |
| Jazz Pharmaceuticals INC. | $41,324.97 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $29,578.52 | 2022-2025 | Libtayo |
| Astrazeneca Pharmaceuticals LP | $27,975.03 | 2021-2025 | Calquence, Lynparza, Imfinzi |
| Rigel Pharmaceuticals, INC. | $22,910.74 | 2021-2023 | Rezlidhia, Tavalisse |
| Geron Corporation | $19,288.35 | 2025 | Rytelo |
| Celgene Corporation | $18,090.85 | 2021-2025 | Reblozyl, Pomalyst, Opdualag |
| Mirati Therapeutics, INC. | $8,684.72 | 2023-2024 | Krazati |
| Karyopharm Therapeutics INC. | $5,675.46 | 2021-2025 | Xpovio |
Show all 68 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epizyme, INC. | $3,749.02 | 2021-2022 | |
| Johnson & Johnson Health Care Systems INC. | $3,684.35 | 2025 | |
| Genmab U.S., INC. | $3,595.21 | 2023-2025 | Epkinly |
| Merck Sharp & Dohme LLC | $3,299.54 | 2021-2025 | Keytruda, Welireg, Lynparza |
| Ipsen Biopharmaceuticals, INC | $2,978.69 | 2021-2024 | Tazverik, Onivyde |
| Amgen INC. | $2,444.47 | 2021-2023 | Kyprolis, Lumakras, Blincyto |
| Janssen Pharmaceuticals, INC | $1,280.00 | 2025 | |
| Beigene USA, INC. | $1,147.61 | 2022-2023 | Brukinsa |
| Pharmaessentia USA Corporation | $1,096.66 | 2022-2025 | Besremi |
| Adaptive Biotechnologies Corporation | $768.26 | 2021-2025 | Clonoseq |
| Secura Bio, INC. | $741.27 | 2023-2025 | Copiktra |
| Janssen Scientific Affairs, LLC | $698.75 | 2021-2024 | Darzalex, Tecvayli, Imbruvica |
| Eisai INC. | $617.64 | 2021-2025 | |
| Lilly USA, LLC | $561.56 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Pfizer INC. | $557.75 | 2021-2025 | |
| Seagen INC. | $480.53 | 2021-2023 | Adcetris |
| Novartis Pharmaceuticals Corporation | $454.79 | 2021-2025 | |
| Gilead Sciences, INC. | $431.02 | 2022-2025 | Trodelvy |
| Abbvie INC. | $409.71 | 2023-2025 | |
| Astellas Pharma US INC | $381.32 | 2021-2025 | Xtandi |
| Tg Therapeutics, INC. | $285.66 | 2021-2022 | |
| Daiichi Sankyo INC. | $263.93 | 2022-2025 | Enhertu |
| Pharmacosmos Therapeutics INC. | $181.93 | 2021-2025 | Monoferric, Cosela |
| Genzyme Corporation | $174.39 | 2021-2025 | |
| Array Biopharma INC | $162.58 | 2021-2025 | Braftovi, Mektovi, Tukysa |
| Tempus Ai, INC | $152.15 | 2024 | |
| Kite Pharma, INC. | $141.22 | 2021-2025 | Yescarta |
| Genentech USA, INC. | $135.72 | 2022-2024 | Tecentriq, Venclexta, Tecentriq Hybreza |
| Stemline Therapeutics INC. | $131.02 | 2023-2025 | Orserdu |
| Morphosys, US INC. | $125.91 | 2021-2023 | Monjuvi |
| Deciphera Pharmaceuticals INC. | $122.20 | 2023-2025 | Qinlock, Tgct |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.84 | 2022-2024 | Gilotrif |
| Bayer Healthcare Pharmaceuticals INC. | $97.32 | 2023-2025 | |
| Emd Serono, INC. | $89.12 | 2023-2024 | Bavencio, Tepmetko |
| Servier Pharmaceuticals LLC | $86.43 | 2024-2025 | |
| Kyowa Kirin, INC. | $70.52 | 2023-2025 | Poteligeo |
| Pharmacyclics LLC, An Abbvie Company | $48.17 | 2021-2023 | Imbruvica |
| Beone Medicines USA, INC. | $45.33 | 2025 | Brukinsa |
| Blueprint Medicines Corporation | $30.66 | 2021-2023 | Ayvakit |
| Puma Biotechnology, INC. | $25.81 | 2025 | |
| Syndax Pharmaceuticals, INC. | $25.29 | 2025 | |
| Exelixis INC. | $23.44 | 2022 | |
| Shield Therapeutics INC | $21.97 | 2024 | |
| Alexion Pharmaceuticals, INC. | $20.32 | 2023 | Ultomiris |
| Adc Therapeutics America, INC. | $18.16 | 2024 | |
| Caris Mpi, INC. | $17.52 | 2025 | Mi Cancer Seek |
| Taiho Oncology, INC. | $17.52 | 2023 | |
| Tolmar Pharmaceuticals, INC. | $17.44 | 2022 | |
| Acceleron Pharma, INC. | $17.32 | 2021 | |
| Pharmaand Gmbh | $17.30 | 2025 | Rubraca |
| Tolmar, INC. | $17.30 | 2025 | Rubraca, Eligard |
| Spectrum Pharmaceuticals INC. | $17.21 | 2025 | Rolvedon |
| G1 Therapeutics, INC. | $14.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.